Ultimovacs Future Growth

Future criteria checks 2/6

Ultimovacs is forecast to grow earnings and revenue by 28.5% and 40.7% per annum respectively. EPS is expected to grow by 79.2% per annum. Return on equity is forecast to be -30.4% in 3 years.

Key information

28.5%

Earnings growth rate

79.2%

EPS growth rate

Biotechs earnings growth	-9.1%
Revenue growth rate	40.7%
Future return on equity	-30.4%
Analyst coverage	Low
Last updated	27 May 2024

Recent future growth updates

Recent updates

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23

Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Feb 13

Earnings and Revenue Growth Forecasts

OB:ULTI - Analysts future estimates and past financials data (NOK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-110	-110	-110	1
12/31/2025	87	-72	-80	-79	1
12/31/2024	N/A	-147	-193	-182	1
3/31/2024	N/A	-178	-199	-199	N/A
12/31/2023	N/A	-189	-190	-190	N/A
9/30/2023	N/A	-204	-197	-197	N/A
6/30/2023	N/A	-186	-197	-197	N/A
3/31/2023	N/A	-165	-159	-159	N/A
12/31/2022	N/A	-168	-168	-168	N/A
9/30/2022	N/A	-148	-152	-152	N/A
6/30/2022	N/A	-153	-145	-145	N/A
3/31/2022	N/A	-168	-142	-142	N/A
12/31/2021	N/A	-165	-126	-126	N/A
9/30/2021	N/A	-138	-105	-105	N/A
6/30/2021	N/A	-126	-102	-102	N/A
3/31/2021	N/A	-124	-110	-105	N/A
12/31/2020	N/A	-121	-114	-108	N/A
9/30/2020	N/A	-121	-114	-108	N/A
6/30/2020	N/A	-108	-102	-97	N/A
3/31/2020	N/A	-77	-80	-79	N/A
12/31/2019	N/A	-61	-63	-63	N/A
9/30/2019	N/A	-48	-59	-59	N/A
6/30/2019	N/A	-48	-57	-56	N/A
3/31/2019	N/A	-59	-55	-55	N/A
12/31/2018	N/A	-55	-51	-50	N/A
9/30/2018	N/A	-50	-46	-45	N/A
6/30/2018	N/A	-42	-38	-38	N/A
3/31/2018	N/A	-35	-32	-32	N/A
12/31/2017	N/A	-33	N/A	-27	N/A
12/31/2016	N/A	-29	N/A	-31	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ULTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ULTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ULTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ULTI's revenue (40.7% per year) is forecast to grow faster than the Norwegian market (1.6% per year).

High Growth Revenue: ULTI's revenue (40.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ULTI is forecast to be unprofitable in 3 years.

Ultimovacs Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Price target decreased by 8.6% to kr155

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

No longer forecast to breakeven

Recent updates

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program

Price target decreased by 8.6% to kr155

New minor risk - Market cap size

Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma

New minor risk - Share price stability

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma

Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma

Ultimovacs ASA to Report Q4, 2024 Results on Feb 13, 2025

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Chief Executive Officer recently bought kr57k worth of stock

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma

Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid

Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)

New minor risk - Share price stability

Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine

Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma

Ultimovacs ASA Announces the Results from Uv1 Phase Ii Clinical Trial Nipu in Malignant Mesothelioma Will Be Presented At the Esmo Congress 2023

Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients

Ultimovacs ASA Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results

Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine

New minor risk - Share price stability

Ultimovacs ASA Provides Update on Phase II NIPU Trial Evaluating UV1 in Second-Line Patients with Malignant Leural Mesothelioma

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Ultimovacs ASA Announces Cemiplimab to Replace Pembrolizumab in V1 Phase II LUNGVAC Trial

Ultimovacs ASA Completes Last Patient Enrollment in Phase I TENDU Trial in Prostate Cancer

Chief Executive Officer recently bought kr145k worth of stock

Forecast to breakeven in 2023

No independent directors

No longer forecast to breakeven

Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs ASA Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs ASA Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

Chief Executive Officer recently bought kr134k worth of stock

Price target increased to kr151

Ultimovacs ASA Expands High Dose Cohort Size in Tendu Phase I Prostate Cancer Trial After Safety Review

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

Ultimovacs ASA Announces UV1 Cancer Vaccine Shows Strong Overall Survival in Malignant Melanoma Phase I Trial

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data At Cancer Immunotherapy Annual Meeting

Price target increased to kr151

No independent directors

Ultimovacs ASA Approves Board and Committee Changes

Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

Chief Executive Officer recently bought kr94k worth of stock

Ultimovacs ASA Completes Treatment of the Second Dose Cohort in the Phase I TENDU Trial

Ultimovacs ASA Announces First Patient Enrolled in Phase II DOVACC Trial of UV1 in Advanced Ovarian Cancer

Chief Executive Officer recently bought kr228k worth of stock

Ultimovacs Asa Announces Further Positive Topline Results from Phase I Uv1 Cancer Vaccine Combination Study in Metastatic Melanoma

Ultimovacs Announces First Patient Enrolled in Phase II Focus Trial of UV1 in Head-And-Neck Cancer

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines

Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

Ultimovacs ASA Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

Deputy Board Member recently bought kr388k worth of stock

Chief Executive Officer recently bought kr91k worth of stock

Forecast to breakeven in 2023